Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis

NCT06867991 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Anti-N-Methyl-D-Aspartate Receptor Encephalitis

Interventions

DRUG: Ofatumumab combined with daratumumab
DRUG: Ofatumumab
DRUG: Repeated intravenous immunoglobulin/plasma exchange therapy

Sponsor

The First People's Hospital of Changzhou